The global authority on nicotinamide adenine
dinucleotide (NAD+) and healthy aging research, ChromaDex, and the
#1 selling pet supplement brand in the USA*, Zesty Paws®,
debut cellular health supplement featuring ChromaDex’s industry
leading healthy aging ingredient, Niagen®
ChromaDex Corp. (NASDAQ:CDXC), the global authority on
nicotinamide adenine dinucleotide (NAD+) and healthy aging
research, and Zesty Paws®, the #1 Selling Pet Supplement
Brand in the USA*, are entering the longevity category, a highly
desirable consumer segment, with the debut of Healthy Aging NAD+
Precursor, featuring ChromaDex’s industry leading cellular
health ingredient, Niagen (patented nicotinamide riboside or NR).
This supplement can help promote metabolic health and cellular
energy and repair for dogs.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20231026661018/en/
ChromaDex and Zesty Paws® launch Healthy
Aging NAD+ Precursor supplement for dogs (Photo: Business Wire)
NAD+ is an essential coenzyme that plays a vital role in
cellular processes including mitochondrial function, cellular
energy production, and DNA repair. Backed by the highest scientific
rigor and quality standards, the key ingredient in this supplement
is Niagen, which is formulated to help support the regeneration of
NAD+ levels in dogs.
“We remain steadfast in our mission to provide the
transformative power of our precious Niagen (NR) ingredient to
every animal cell on this planet, including to our beloved canine
companions,” said ChromaDex CEO, Rob Fried. “As the global
authority on NAD+ and healthy aging research, and the creators of
the most superior and efficient NAD+ booster, we are proud to
partner with Zesty Paws to enhance the healthy aging journey for
our pooches.”
Bob Kalil, vice president of product development for Zesty Paws
(part of H&H Group), said, “By combining the ideals of science
and nature and upholding the brand’s commitment of quality and
trusted ingredients included in every formula, we were able to
create a groundbreaking product that benefits the healthy aging of
dogs inside and out. While this category is in its early stages,
our product innovation is a very exciting example of what’s to come
for supporting longevity for pets.”
The Healthy Aging NAD+ Precursor pack from Zesty Paws,
that launched exclusively with Chewy this month, includes one
bottle of 60 capsules of Niagen (NR) and one jar of the brand’s
bacon-flavored Pill Wrap Probiotic Paste.
“Our Healthy Aging line was designed to bring a bit of your
dog’s puppyhood back. By replenishing their NAD+ levels, this
breakthrough innovation can help promote cell regeneration and
support healthy aging, allowing our beloved pets to maintain their
vitality and zest for life,” said Yvethe Tyszka, vice president of
marketing for Zesty Paws (part of H&H Group).
The Healthy Aging line will expand in early 2024 with additional
distribution and the launch of a powdered format.
For additional information on Niagen, visit Chromadex.com
and for more information about Zesty Paws, please visit
ZestyPaws.com.
About ChromaDex
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
About H&H Group, North
America
H&H Group is a global health and nutrition company with
three growing business segments in North America – Baby, Adult and
Pet Nutrition and Care – supporting whole-family health and
happiness through premium brands providing nutrition and wellness
solutions backed by science to pets and people. The consumer brands
include Zesty Paws, the #1 Selling Pet Supplement Brand in the
USA*, Solid Gold Pet, America’s first holistic pet nutrition
company, as well as children’s nutrition brand, Biostime, and
vitamin, supplement, and skincare brand, Swisse.
*Source Euromonitor International Limited; Pet Supplements
category as per Passport Ecommerce. All channels included,
excluding vets, volume sales in units, more info at
https://zestypaws.com/pages/claim.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to the launch of Niagen in
the pet segment. Statements that are not a description of
historical facts constitute forward-looking statements and may
often, but not always, be identified by the use of such words as
"expects," "anticipates," "intends," "estimates," "plans,"
"potential," "possible," "probable," "believes," "seeks," "may,"
"will," "should," "could" or the negative of such terms or other
similar expressions. Risks that contribute to the uncertain nature
of these forward-looking statements include the impact of the
COVID-19 pandemic on our business and the global economy; our
history of operating losses and need to obtain additional
financing; the growth and profitability of our product sales; our
ability to maintain sales, marketing and distribution capabilities;
changing consumer perceptions of our products; our reliance on a
single or limited number of third-party suppliers; and the risks
and uncertainties associated with our business and financial
condition. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2022, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231026661018/en/
ChromaDex Media Contact: Kendall Knysch, Head of Media
Relations & Partnerships 310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact: +1 (949) 356-1620
InvestorRelations@ChromaDex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2023 to Apr 2024